- Open Access
Microglial responses to amyloid β peptide opsonization and indomethacin treatment
© Strohmeyer et al; licensee BioMed Central Ltd. 2005
- Received: 18 June 2005
- Accepted: 19 August 2005
- Published: 19 August 2005
Recent studies have suggested that passive or active immunization with anti-amyloid β peptide (Aβ) antibodies may enhance microglial clearance of Aβ deposits from the brain. However, in a human clinical trial, several patients developed secondary inflammatory responses in brain that were sufficient to halt the study.
We have used an in vitro culture system to model the responses of microglia, derived from rapid autopsies of Alzheimer's disease patients, to Aβ deposits.
Opsonization of the deposits with anti-Aβ IgG 6E10 enhanced microglial chemotaxis to and phagocytosis of Aβ, as well as exacerbated microglial secretion of the pro-inflammatory cytokines TNF-α and IL-6. Indomethacin, a common nonsteroidal anti-inflammatory drug (NSAID), had no effect on microglial chemotaxis or phagocytosis, but did significantly inhibit the enhanced production of IL-6 after Aβ opsonization.
These results are consistent with well known, differential NSAID actions on immune cell functions, and suggest that concurrent NSAID administration might serve as a useful adjunct to Aβ immunization, permitting unfettered clearance of Aβ while dampening secondary, inflammation-related adverse events.
- Formyl Peptide Receptor
- Microglial Culture
- Microglial Migration
- Bright Field Optic
Chemotactic and phagocytic responses of microglia to amyloid β peptide (Aβ) have been inferred from postmortem autopsy evaluations [1–3], animal studies [4, 5], and an in vitro model in which cultured rodent microglia were placed directly on Alzheimer's disease (AD) cortical sections [5, 6]. Although these valuable experiments confirm that microglia cluster around and may help clear Aβ deposits, new questions have arisen concerning the effects of various agents on these microglial interactions with Aβ. In particular, several studies have indicated that the opsonization of Aβ deposits with anti-Aβ antibodies facilitates microglia-mediated Aβ clearance [6, 7]. Here, binding of the antibodies to the Aβ target presumably enhances microglial recognition of and subsequent responses to the target through Fc receptors expressed by the microglia [6, 7]. Based on these results, it has been suggested that microglial responses to Aβ might represent so beneficial an inflammatory action that anti-inflammatory drugs might actually be detrimental as a treatment for AD . Alternatively, multiple epidemiologic studies [9, 10] have reported decreased risk for AD in persons who take common nonsteroidal anti-inflammatory drugs (NSAIDs).
Over the last decade, our laboratory has developed reliable methods for culturing microglia from rapid (< 4 hour) brain autopsies of AD patients [11, 12]. These cultures uniquely match the species, developmental stage, and disease state of AD subjects, and provide the ready experimental manipulability that is helpful in assessing complex physiologic processes such as chemotaxis, phagocytosis, secretory activity, and drug responses. In order to quantitatively assay these processes in the context of microglial interactions with Aβ, we seeded AD microglial cultures into wells containing pre-aggregated Aβ1-42 spots dried down to the well floor. Subsequent experiments measured migration of the cells to the Aβ spots, phagocytosis of the Aβ spots, pro-inflammatory cytokine secretion, and the effects on these processes when Aβ spots were opsonized with an anti-Aβ antibody or when microglia were treated with a common nonsteroidal anti-inflammatory drug (NSAID), indomethacin. Overall, opsonization with Aβ antibody enhanced microglial migration to and phagocytosis of Aβ. Indomethacin had little to no effect on these responses, but did significantly inhibit microglial secretion of IL-6.
AD microglia cultures
Cultures of microglia from rapid (< 4 hours) autopsies of six antemortem-evaluated, neuropathologically-confirmed AD patients were prepared using our previously published methods [11, 12]. By immunoreactivity, these cultures are consistently negative for neuron, astrocyte, oligodendrocyte, and fibroblast markers, consistently positive for multiple markers of activated microglia, and readily maintained at purities of 98% or higher [11, 12]. Microglia cultures from all six AD patients were used for biochemical assays. Additional cultures from one of these patients were used for quantitative evaluation of chemotaxis and phagocytosis, and additional cultures from two more of these patients were used for qualitative replication of the chemotaxis and phagocytosis results. At 3–7 days post-plating, the microglia were trypsinized and replated at 50,000 cells/well in 12-well plates. Prior to replating, 2 μl of a 1 mM solution of Aβ1-42 (Bachem) in PBS (pH 7.4) was dried down to the well floor. Each well received two such Aβ spots, and there were three wells per experimental condition, so that a total of six Aβ spots were quantified per experimental condition. Serum-free medium was used throughout the experiments. Control wells containing no Aβ or no microglia were also prepared.
Treatment with anti-Aβ antibody
Prior to seeding with microglia, selected wells were pretreated with vehicle (medium) only or with 10 μg/ml 6E10 (Signet Laboratories), a mouse monoclonal antibody directed against the first 17 (N-terminal) amino acids in the Aβ sequence. In some experiments, a 2 μg/ml concentration of 6E10 was included in order to evaluate effects at a lower dose.
Treatment with indomethacin
Prior to seeding with microglia, selected wells were pretreated with vehicle (medium) only or with 1.0 μg/ml indomethacin. Indomethacin, at 1.0 μg/ml, and vehicle were also replenished at Days 3, 6, and 9 in the course of medium changes. The 1.0 μg/ml indomethacin concentration is at the upper end of the physiologically normal range achieved in blood after therapeutic doses of the drug , and was chosen to insure that any failure of indomethacin to affect chemotaxis to or phagocytosis of Aβ was not due to inadequate drug dosage. In some experiments, a 0.1 μg/ml concentration of indomethacin, which is at the lower end of the physiologically normal range achieved in blood after therapeutic doses, was included in order to evaluate effects at a lesser concentration.
Cytochemistry and immunocytochemistry
For qualitative evaluations of microglial responses to Aβ, microglial cultures were briefly fixed with 4% buffered paraformaldehyde, then immunoreacted overnight with 1:1000 (0.5 μg/ml) LN3 antibody (MP Biomedical) directed against the major histocompatibility complex type II cell surface glycoprotein, using our previously published methods [11, 14, 15]. Vectastain ABC kits (Vector Laboratories) were employed using the manufacturer's protocols to detect immunoreactivity with bright field optics. Aβ spots could be sufficiently resolved under these conditions by their modest opaqueness under bright field optics. To visualize Aβ spots in phagocytosis experiments, the wells were washed gently in distilled water (3 × for 5 min each), incubated with 0.1% Thioflavine S (Sigma) for 10 min, washed once in distilled water (5 min), then dehydrated and fixed with 4% buffered paraformaldehyde. In additional experiments, Aβ immunocytochemistry was applied in selected wells so as to graphically illustrate Aβ removal and microglial uptake of Aβ. In these studies, microglial cultures with Aβ spots were briefly fixed with 4% buffered paraformaldehyde and incubated overnight with 1:1000 (1 μg/ml) anti-Aβ antibody 4G8 (Signet Laboratories). Detection of immunoreactivity was accomplished using Vectastain ABC kits (Vector Laboratories) and the manufacturer's suggested protocols.
Microglial migration to Aβ spots
Tests of microglial proliferation
BrdU staining kits (Zymed/Invitrogen) were applied to selected wells in order to assess whether shifts in microglial distributions over time might be due to differential proliferation of microglia relative to Aβ spots as opposed to migration of the cells. Staining with BrdU followed the manufacturer's recommended directions.
Microglial phagocytosis of Aβ spots
At Day 12 postplating, selected wells were histochemically reacted with Thioflavine S, as described earlier, and visualized at 100 × (10 × objective) with a confocal microscope. Using the ability of the confocal microscope to optically section an object at precise distances, the number of 10 μm optical slices from the well floor to the top of the remaining Aβ spot was recorded by an investigator blinded to the experimental conditions imposed in each well. The data were then assessed statistically using 2-way ANOVAs, with spot thickness as the outcome measure, antibody treatment (vehicle only, 2 μg/ml anti-A↕ IgG, or 10 μg/ml anti-A↕ IgG) as the first factor, and NSAID treatment (vehicle only, 0.1 μg/ml indomethacin, or 1.0 μg/ml indomethacin) as the second factor.
Microglial secretion of cytokines
To assess the effects of opsonization with anti-Aβ antibodies, microglial cultures were preincubated with vehicle or 10 μg/ml anti-Aβ monoclonal 6E10 followed by 4 hours exposure to 0 or 10 μM preaggregated Aβ1-42 (Bachem). Conditioned medium was then subjected to TNF-α ELISA (R&D Systems) using the manufacturer's protocols. To confirm the results with another pro-inflammatory cytokine, and to evaluate the interaction of indomethacin with antibody opsonization, microglial cultures were preincubated with vehicle or 10 μg/ml 6E10, as before, but in the presence or absence of 1 μg/ml indomethacin. After incubation for 4 hours with 0 or 10 μM Aβ1-42, the conditioned medium was subjected to IL-6 ELISA (R&D Systems) using the manufacturer's protocols.
Microglial migration to Aβ spots
Effects of opsonization with anti-Aβ antibody 6E10 on chemotaxis-like changes in microglia distributions
0 μg/ml anti-Aβ
2 μg/ml anti-Aβ
10 μg/ml anti-Aβ
0 μg/ml anti-Aβ
2 μg/ml anti-Aβ
10 μg/ml anti-Aβ
Differential proliferation versus chemotaxis
Proliferation of microglia more proximal to the Aβ spots, rather than true chemotaxis, did not explain the shifts in microglial distributions that were exhibited over time under the various treatment conditions. There was little to no BrdU staining under any condition (not shown) and, in fact, there was a slight but significant decrease in microglial numbers in all treatment conditions and overall from Day 3 (mean microglial density/0.25 mm2 grid square = 40.8 ± 0.3) to Day 9 (mean microglial density/0.25 mm2 grid square = 37.8 ± 0.4) (FOverall = 34.5, P = 0.000). Consistent with our previous experience, AD microglia stimulated with M-CSF as a positive control showed little to no evidence of proliferation. However, M-CSF-stimulated THP-1 cells (a monocyte line often used as a surrogate for microglia) that were run in parallel did show clear proliferation under the same BrdU assay conditions (data not shown).
Microglial phagocytosis of Aβ
Microglial secretion of cytokines
The present study found that AD microglia in vitro migrate toward Aβ aggregates, attempt to phagocytose the aggregates, and increase their secretion of TNF-α and IL-6 in the process. Opsonization of Aβ aggregates with anti-Aβ antibody 6E10 significantly enhanced these processes. By contrast, the common NSAID indomethacin had no material or statistical effect on microglial migration or phagocytosis, but significantly inhibited the increased IL-6 secretion observed with anti-Aβ opsonization.
The shifts in microglial distributions relative to Aβ spots over time are most parsimoniously explained by chemotactic responses to Aβ. Proliferation of microglia more proximal to Aβ aggregates was not observed and, in fact, BrdU reactivity, a common marker for cell proliferation, was negligible at all distances from the aggregates. Chemokinesis, enhanced but undirected movement of cells, also did not appear to explain the results, since microglial migration exhibited the gradient characteristics of chemotaxis, with progressive increases in the density of microglia at distances more proximal to Aβ aggregates. In addition, microglia are now well established to express receptors that can mediate chemotactic behaviors and that appear to have Aβ as a ligand. These include the macrophage scavenger receptor [16–18], the receptor for advanced glycation endproducts (RAGE) , the formyl peptide receptor , and others [20, 21]. RAGE, in particular, has been shown to help mediate microglial migration to Aβ spots in an in vitro paradigm similar to that used here, and this migration could be inhibited by anti-RAGE Fab fragments .
AD microglia in vitro also exhibited behaviors consistent with phagocytosis of Aβ aggregates. Entering the paradigm, the microglia showed little or no Aβ immunoreactivity. After 12 days incubation with Aβ spots, the microglia were highly immunoreactive for Aβ and the spots decreased in size. Aβ spots without microglia remained essentially intact over the same time period. Previous ultrastructural and other studies [3, 22, 23] have also identified Aβ filaments within microglia in the vicinity of Aβ deposits in AD cortex. Although it remains possible that the intracellular Aβ within microglia in the AD brain may have been produced by the cells  rather than phagocytosed from an extracellular deposit, this is clearly not the process observed in the present in vitro studies. We conclude, therefore, that AD microglia in vitro do phagocytose aggregated Aβ deposits. Given the experimental accessibility of the model, it will be of interest in future to evaluate the molecular fate of phagocytosed Aβ in cultured AD microglia.
Exposure to aggregated Aβ also induced significant increases in TNF-α and IL-6 secretion, confirming our previous experiments  and those of others [25–27] with TNF-α, IL-6, and a broad range of chemokines, cytokines, and inflammatory toxins such as reactive oxygen/nitrogen species. Pathways for enhancing TNF-α and IL-6 secretion have been demonstrated, including NF-kB and C/EBP transcriptional mechanisms, both of which are enhanced in pathologically-vulnerable regions of the AD brain [28, 29].
Opsonization of Aβ spots with anti-Aβ antibody 6E10 significantly enhanced microglial migration to the spots, phagocytosis of the spots, and cytokine secretion. Similar effects of opsonization on microglial migration and phagocytosis have also been reported using anti-Aβ antibodies and an in vitro preparation in which cultured rodent microglia were seeded onto postmortem AD cortex sections laden with Aβ deposits . Soluble Fab fragments containing the Fc region ligand for Fc receptor binding inhibited Aβ removal in this paradigm. These effects are consistent with the classic mechanisms of antibody opsonization of immune targets by antibodies specific to epitopes on the target. Scavenger cells that express receptors to the Fc region of the antibodies are then directed to or become focused at the site where the antibody-bound target resides. Fc receptor activation, in addition, activates scavenger cells, promoting attack and phagocytosis. Recently, scientists at Elan Pharmaceuticals have attempted to harness these mechanisms to enhance Aβ clearance, using immunization with Aβ to drive production of anti-Aβ antibodies for subsequent Aβ opsonization [6, 30]. Although there is controversy about the exact site of action of the antibodies (e.g., brain versus peripheral circulation) [6, 30, 31], this approach does clearly result in significant and sometimes dramatic reductions of Aβ burden in transgenic mouse models , as well as the in vitro model tested here, and may also have been effective in human patients receiving Aβ immunization .
Unfortunately, however, inflammatory responses are often a two-edged sword. Fc receptor binding is known to enhance the activation and pro-inflammatory secretory responses of scavenger cells that bear Fc receptors, and microglia do express these receptors [6, 32]. The increased TNF-α and IL-6 secretion observed in the present experiments after opsonization of Aβ aggregates with a specific anti-Aβ antibody, 6E10, is therefore not unexpected. On activation, microglial cells are, in fact, well established to secrete a wide range of inflammatory mediators that could not only cause damage to neurons and neurites locally, but also, if sufficiently activated, provide signalling to peripheral immune cells to provoke a more generalized and severe response such as that reported in several Aβ-immunized patients who experienced lethal adverse reactions .
The vast majority of NSAIDs in use today are based on the principle of cyclooxygenase inhibition, and cyclooxygenase inhibition, in turn, is well established to downregulate a wide range of acute phase reactants. Interestingly, however, mechanisms for chemotaxis to and phagocytosis of an inflammatory target are not necessarily cyclooxygenase dependent. In a survey, for example, of the first 100 publications retrieved from PubMed using the search phrase "indomethacin AND chemotaxis", the majority of studies found no effect of indomethacin on chemotaxis, and some of the papers actually reported enhanced chemotaxis after indomethacin exposure. Such findings have been suggested to explain why physicians commonly prescribe NSAIDs to control fever and other secondary inflammatory responses without being unduly concerned about hampering immune-mediated removal of the fever-inducing agent. Similarly, in the present experiments indomethacin had no material or statistically significant effect on microglial chemotaxis to or phagocytosis of Aβ aggregates, but did significantly inhibit the exacerbated IL-6 response under opsonized conditions. Although it is never certain that in vitro results will fully apply to the in vivo state, these results suggest that indomethacin or an NSAID like it might be a useful adjunct to Aβ immunization strategies.
This research was directly supported by NIA AGO7367. Institutional support for Alzheimer's research was provided by the Arizona Alzheimer's Disease Core Center (P30 AG019610) (NIA) and the Arizona Alzheimer's Consortium (State of Arizona). We thank Kyle Mueller, Gita Seetharaman, and Leyla Descheny for technical assistance, and Dr. Emily Lue and Dr. Douglas Walker for technical advice.
- Luber-Narod J, Rogers J: Immune system associated antigens expressed by cells of the human central nervous system. Neurosci Lett. 1988, 94: 17-22. 10.1016/0304-3940(88)90263-7.View ArticlePubMedGoogle Scholar
- Rogers J, Luber-Narod J, Styren SD, Civin WH: Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988, 9: 339-349.View ArticlePubMedGoogle Scholar
- Terry RD, Wisniewski HM: Structural and chemical changes of the aged human brain. Psychopharmacol Bull. 1975, 11: 46-63.PubMedGoogle Scholar
- Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW: Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci. 1998, 18: 2161-2173.PubMedGoogle Scholar
- Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD: Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. J Neurosci Res. 1996, 43: 190-202. 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B.View ArticlePubMedGoogle Scholar
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000, 6: 916-919. 10.1038/78682.View ArticlePubMedGoogle Scholar
- Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T: Epitope and isotype specificities of antibodies to beta – amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A. 2003, 100: 2023-2028. 10.1073/pnas.0436286100.PubMed CentralView ArticlePubMedGoogle Scholar
- Schenk DB, Yednock T: The role of microglia in Alzheimer's disease: friend or foe?. Neurobiol Aging. 2002, 23: 677-679. 10.1016/S0197-4580(02)00034-9.View ArticlePubMedGoogle Scholar
- McGeer EG, McGeer PL: Clinically tested drugs for Alzheimer's disease. Expert Opin Investig Drugs. 2003, 12: 1143-1151.View ArticlePubMedGoogle Scholar
- McGeer EG, McGeer PL: Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des. 1999, 5: 821-836.PubMedGoogle Scholar
- Lue LF, Brachova L, Walker DG, Rogers J: Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients. Neurobiol Aging. 1996, 17: 421-429. 10.1016/0197-4580(96)00006-1.View ArticlePubMedGoogle Scholar
- Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J: Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia. 2001, 35: 72-79. 10.1002/glia.1072.View ArticlePubMedGoogle Scholar
- Bruguerolle B, Barbeau G, Belanger PM, Labrecque G: Pharmacokinetics of a sustained-release product of indomethacin in the elderly. Gerontology. 1986, 32: 277-285.View ArticlePubMedGoogle Scholar
- Lue LF, Brachova L, Civin WH, Rogers J: Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996, 55: 1083-1088.View ArticlePubMedGoogle Scholar
- Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD: Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol. 2001, 171: 29-45. 10.1006/exnr.2001.7732.View ArticlePubMedGoogle Scholar
- Honda M, Akiyama H, Yamada Y, Kondo H, Kawabe Y, Takeya M, Takahashi K, Suzuki H, Doi T, Sakamoto A, Ookawara S, Mato M, Gough PJ, Greaves DR, Gordon S, Kodama T, Matsushita M: Immunohistochemical evidence for a macrophage scavenger receptor in Mato cells and reactive microglia of ischemia and Alzheimer's disease. Biochem Biophys Res Commun. 1998, 245: 734-740. 10.1006/bbrc.1998.8120.View ArticlePubMedGoogle Scholar
- Christie RH, Freeman M, Hyman BT: Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am J Pathol. 1996, 148: 399-403.PubMed CentralPubMedGoogle Scholar
- El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD: Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996, 382: 716-719. 10.1038/382716a0.View ArticlePubMedGoogle Scholar
- Lorton D, Schaller J, Lala A, DeNardin E: Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's disease. Neurobiol Aging. 2000, 21: 463-473. 10.1016/S0197-4580(00)00092-0.View ArticlePubMedGoogle Scholar
- Koenigsknecht J, Landreth G: Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004, 24: 9838-9846. 10.1523/JNEUROSCI.2557-04.2004.View ArticlePubMedGoogle Scholar
- Bourin M, Ripoll N, Dailly E: Nicotinic receptors and Alzheimer's disease. Curr Med Res Opin. 2003, 19: 169-177. 10.1185/030079903125001631.View ArticlePubMedGoogle Scholar
- Cole GM, Beech W, Frautschy SA, Sigel J, Glasgow C, Ard MD: Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro. J Neurosci Res. 1999, 57: 504-520. 10.1002/(SICI)1097-4547(19990815)57:4<504::AID-JNR10>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
- Wisniewski HM, Terry RD: Morphology of the aging brain, human and animal. Prog Brain Res. 1973, 40: 167-186.View ArticlePubMedGoogle Scholar
- Banati RB, Gehrmann J, Czech C, Monning U, Jones LL, Konig G, Beyreuther K, Kreutzberg GW: Early and rapid de novo synthesis of Alzheimer beta A4-amyloid precursor protein (APP) in activated microglia. Glia. 1993, 9: 199-210. 10.1002/glia.440090305.View ArticlePubMedGoogle Scholar
- Ito S, Sawada M, Haneda M, Fujii S, Oh-Hashi K, Kiuchi K, Takahashi M, Isobe K: Amyloid-beta peptides induce cell proliferation and macrophage colony-stimulating factor expression via the P13-kinase/Akt pathway in cultured Ra2 microglial cells. FEBS Lett. 2005, 579: 1995-2000. 10.1016/j.febslet.2005.02.048.View ArticlePubMedGoogle Scholar
- Floden AM, Li S, Combs CK: Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci. 2005, 25: 2566-2575. 10.1523/JNEUROSCI.4998-04.2005.View ArticlePubMedGoogle Scholar
- Mrak RE, Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005, 26: 349-354. 10.1016/j.neurobiolaging.2004.05.010.View ArticlePubMedGoogle Scholar
- Li R, Strohmeyer R, Liang Z, Lue LF, Rogers J: CCAAT/enhancer binding protein delta (C/EBP delta) expression and elevation in Alzheimer's disease. Neurobiol Aging. 2004, 25: 991-999. 10.1016/j.neurobiolaging.2003.10.016.View ArticlePubMedGoogle Scholar
- Bales KR, Du Y, Holtzman D, Cordell B, Paul SM: Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging. 2000, 21: 427-430. 10.1016/S0197-4580(00)00143-3.View ArticlePubMedGoogle Scholar
- Masliah E, Hansen L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D: Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer's disease. Neurology. 2005, 64: 129-131.View ArticlePubMedGoogle Scholar
- DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001, 98: 8850-8855. 10.1073/pnas.151261398.PubMed CentralView ArticlePubMedGoogle Scholar
- Song X, Tanaka S, Cox D, Lee SC: Fcgamma receptor signaling in primary human microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and chemokine induction. J Leukoc Biol. 2004, 75: 1147-1155. 10.1189/jlb.0403128.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.